https://nova.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54297 Wed 28 Feb 2024 15:52:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51366 Wed 28 Feb 2024 15:46:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53799 Wed 28 Feb 2024 15:24:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45252 Wed 26 Oct 2022 17:55:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45003 n = 19), including 7 with NEA and healthy controls (n = 10) underwent a clinical assessment, venepuncture and sputum induction. MDMs were co-cultured with apoptotic granulocytes isolated from healthy donors with or without exogenous recombinant galectin-3 (50 μg/mL) and efferocytosis was assessed by flow cytometry. Galectin-3 expression and localisation in MDMs was visualised by immunofluorescence staining and fluorescence microscopy. Galectin-3, interleukin (IL)-6 and CXCL8 secretion were measured in cell culture supernatants by ELISA and cytometric bead array. Results: Baseline efferocytosis (mean (±standard deviation)) was lower in participants with asthma (33.2 (±17.7)%) compared with healthy controls (45.3 (±15.9)%; p = 0.081). Efferocytosis did not differ between the participants with eosinophilic asthma (EA) (31.4 (±19.2)%) and NEA (28.7 (±21.5)%; p = 0.748). Addition of galectin-3 significantly improved efferocytosis in asthma, particularly in NEA (37.8 (±18.1)%) compared with baseline (30.4 (±19.7)%; p = 0.012). Efferocytosis was not associated with any of the clinical outcomes but was negatively correlated with sputum macrophage numbers (Spearman r = − 0.671; p = 0.017). Galectin-3 was diffusely distributed in most MDMs but formed punctate structures in 5% of MDMs. MDM galectin-3 secretion was lower in asthma (9.99 (2.67, 15.48) ng/mL) compared with the healthy controls (20.72 (11.28, 27.89) ng/mL; p = 0.044) while IL-6 and CXCL8 levels were similar. Conclusions: Galectin-3 modulates macrophage function in asthma, indicating a potential role for galectin-3 to reverse impaired efferocytosis in NEA.]]> Wed 26 Oct 2022 09:42:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:32080 Wed 24 Nov 2021 15:52:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:32651 30 kg/m²). Exacerbations requiring medical intervention were recorded prospectively. Asthma control, medication use, and fractional exhaled nitric oxide were assessed monthly; additional visits occurred during exacerbations. Peripheral blood was collected at baseline for the measurement of eosinophils, soluble CD-163, C-reactive protein, and IL-6. Results: Exacerbations occurred in a higher proportion of overweight (51.1%) and obese (48.4%) women compared with healthy weight women (25%; P =.026). Excess weight gain during pregnancy was not associated with exacerbation risk. Macrophage activation (elevated serum soluble CD-163) was associated with exacerbations requiring oral corticosteroids (P =.043), whereas high peripheral blood eosinophils or fractional exhaled nitric oxide were not associated with exacerbation or oral corticosteroid use. Conclusions: Being overweight or obese confers a greater risk of asthma exacerbation during pregnancy, and may be due to systemic macrophage activation.]]> Wed 19 Jan 2022 15:19:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:31003 Wed 19 Jan 2022 15:18:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52293 Wed 17 Apr 2024 14:31:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48073 Wed 13 Mar 2024 14:25:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48048 Wed 13 Mar 2024 14:19:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38782 Wed 13 Mar 2024 13:54:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46073 Wed 13 Mar 2024 13:53:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47060 Wed 13 Mar 2024 08:04:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:43927 n = 157) and without (n = 79) asthma. Mothers with asthma participated in this study following participation in a randomized controlled trial of a novel asthma management strategy during pregnancy. Mothers completed the Parenting Stress Index Short Form during the first 12 months postpartum. Mothers with asthma also completed the Asthma Control Questionnaire. Results: Parenting stress did not differ between mothers with and without asthma. Additionally, for mothers with asthma, there were no differences in levels of parenting stress based on asthma control. Conclusions: This study suggests that mothers with asthma are not at an increased risk for excessive parenting stress. However, due to response and sampling bias, levels of parenting stress in asthmatic mothers may be underreported in our sample.]]> Wed 13 Mar 2024 08:01:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:15253 Wed 11 Apr 2018 17:15:44 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22041 Wed 11 Apr 2018 16:59:44 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:2764 Wed 11 Apr 2018 16:29:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:12524 Wed 11 Apr 2018 15:30:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10307 Wed 11 Apr 2018 15:17:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:14146 Wed 11 Apr 2018 15:12:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1059 Wed 11 Apr 2018 14:05:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:15377 Wed 11 Apr 2018 13:30:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22224 Wed 11 Apr 2018 13:02:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:28242 Wed 11 Apr 2018 12:02:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:11811 Wed 11 Apr 2018 11:55:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:17382 Wed 11 Apr 2018 11:02:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:19199 Wed 11 Apr 2018 10:44:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22540 Wed 11 Apr 2018 10:17:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:12423 Wed 11 Apr 2018 09:52:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:32663 Wed 10 Nov 2021 15:04:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:41553 Wed 08 May 2024 09:45:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49859 Wed 07 Jun 2023 10:25:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44806 Wed 01 May 2024 12:05:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52880 Tue 31 Oct 2023 10:44:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55205 Tue 30 Apr 2024 10:50:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44917 P <0.001). In conclusion, the consumption of fast foods, particularly hamburgers, correlates to asthma in a dose-response pattern, which needs to be further validated in longitudinal and interventional studies.]]> Tue 25 Oct 2022 09:17:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51001 Tue 15 Aug 2023 12:06:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45225 Thu 27 Oct 2022 15:10:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:29462 IRAKM, PCDH1, ORMDL3/GSDMB, IL-33, CDHR3 and CST1 in airway epithelial cells. Recent studies on epigenetic regulatory factors have further provided novel insights to the field, particularly their effect on regulation of some of the asthma susceptibility genes (e.g. methylation of ADAM33). Among the epigenetic regulatory mechanisms, microRNA networks have been shown to regulate a major portion of post-transcriptional gene regulation. Particularly, miR-19a may have some therapeutic potential.]]> Thu 24 Mar 2022 11:32:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53382 Thu 23 Nov 2023 12:54:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54912 Thu 21 Mar 2024 12:03:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48967 Thu 20 Apr 2023 10:09:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46113 n = 12, defined as per GINA criteria), non-severe uncontrolled (n = 21) and controlled asthma (n = 21) and healthy controls (n = 15). Sputum RNA was extracted and transcriptomic profiles were generated (Illumina HumanRef-8 V2) and analysed (GeneSpring). Sputum protein lysates were analysed for p38 activation in a validation study (n = 24 asthma, n = 8 healthy) by western blotting. Results: There were 2166 genes differentially expressed between the four groups. In severe asthma, the expression of 1875, 1308 and 563 genes was altered compared to healthy controls, controlled and uncontrolled asthma, respectively. Of the 1875 genes significantly different to healthy controls, 123 were >2-fold change from which four networks were identified. Thirty genes (>2-fold change) were significantly different in severe asthma compared to both controlled asthma and healthy controls. There was enrichment of genes in the p38 signalling pathway that were associated with severe asthma. Phosphorylation of p38 was increased in a subset of severe asthma samples, correlating with neutrophilic airway inflammation. Conclusion: Severe asthma is associated with substantial differences in sputum gene expression that underlie unique cellular mechanisms. The p38 signalling pathway may be important in the pathogenesis of severe asthma, and future investigations into p38 inhibition are warranted as a ‘non-Th2’ therapeutic option.]]> Thu 18 Apr 2024 11:56:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:31150 Thu 17 Feb 2022 09:28:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:33763 Thu 17 Feb 2022 09:27:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8221 Thu 11 Jul 2019 11:43:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:30829 Thu 09 Dec 2021 11:04:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:34690 Thu 03 Feb 2022 12:20:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8465 Sat 24 Mar 2018 08:42:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:7384 Sat 24 Mar 2018 08:40:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8459 Sat 24 Mar 2018 08:38:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8668 Sat 24 Mar 2018 08:38:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8664 Sat 24 Mar 2018 08:38:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:7533 Sat 24 Mar 2018 08:38:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8198 Sat 24 Mar 2018 08:36:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1373 Sat 24 Mar 2018 08:28:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:2984 1 week) supplementation trials have been promising. However, the development of techniques to study isoprostanes in airway­lining fluid pave the way for further studies investigating the potential for antioxidant supplements to be used as routine therapy in asthma.]]> Sat 24 Mar 2018 08:27:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:14580 Sat 24 Mar 2018 08:22:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:14509 Sat 24 Mar 2018 08:19:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:16017 Sat 24 Mar 2018 08:19:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:13283 Sat 24 Mar 2018 08:15:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:13284 Sat 24 Mar 2018 08:15:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:16923 Sat 24 Mar 2018 08:00:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:18462 3% and > 61% respectively. Peripheral blood monocytes were isolated (n = 61) and sputum macrophages were isolated from a subgroup of patients with asthma (n = 14), using immunomagnetic cell separation. RNA and nuclear proteins were extracted and quantified. Enzyme activity was assessed using fluorescent assays and gene expression of EP300, KAT2B, CREBBP, and HDACs 1, 2 and 3 were measured by qPCR. Results: There was a significant inverse association between blood monocyte HAT and HDAC activity (r = −0.58, P < 0.001). NA was associated with increased blood monocyte HAT enzyme activity (P = 0.02), decreased HDAC activity (P = 0.03), and increased HAT: HDAC ratio (P < 0.01) compared with eosinophilic asthma. There were no differences in gene expression of EP300, KAT2B, CREBBP, or HDACs 1, 2 and 3 in blood monocytes from subjects with asthma or inflammatory phenotypes of asthma. There was no effect of inhaled corticosteroid use, poor asthma control, or asthma severity on HAT/HDAC activities. Sputum macrophages had increased expression of KAT2B in eosinophilic compared with paucigranulocytic asthma. Conclusions and Clinical Relevance: Neutrophilic airway inflammation is associated with increased HAT and reduced HDAC activity in blood monocytes, demonstrating further systemic manifestations relating to the altered inflammatory gene transcription profile of neutrophilic asthma.]]> Sat 24 Mar 2018 07:59:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:18979 Sat 24 Mar 2018 07:58:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:20875 Sat 24 Mar 2018 07:57:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:20580 Sat 24 Mar 2018 07:55:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:19229 9/L. The blood eosinophil/lymphocyte ratio (ELR) and eosinophil/neutrophil ratio (ENR) were increased in eosinophilic asthma, and the neutrophil/lymphocyte ratio (NLR) was increased in neutrophilic asthma. Neutrophilic asthma could also be detected by blood neutrophil percentages and NLR, but with less accuracy. Conclusions and Clinical Relevance: Blood eosinophil counts and derived ratios (ELR and ENR) can accurately predict eosinophilic asthma in patients with persistent uncontrolled asthma despite treatment. Blood neutrophil parameters are poor surrogates for the proportion of sputum neutrophils. Blood counts may be a useful aid in the monitoring of uncontrolled asthma.]]> Sat 24 Mar 2018 07:54:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:18331 Sat 24 Mar 2018 07:52:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:5604 Sat 24 Mar 2018 07:49:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:5103 Sat 24 Mar 2018 07:48:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:6787 Sat 24 Mar 2018 07:46:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:100 Sat 24 Mar 2018 07:42:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:27857 Sat 24 Mar 2018 07:41:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:4818 Sat 24 Mar 2018 07:18:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22281 Sat 24 Mar 2018 07:17:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22049 Sat 24 Mar 2018 07:15:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22105 Sat 24 Mar 2018 07:10:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48173 Sat 11 Mar 2023 12:23:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38982 Mon 29 Jan 2024 17:51:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38659 Mon 29 Jan 2024 17:49:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38401 Mon 29 Jan 2024 17:48:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47276 Mon 27 Mar 2023 13:58:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54966 Mon 25 Mar 2024 12:11:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:2879 Mon 23 Sep 2019 14:24:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:32745 Mon 23 Sep 2019 14:10:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:34885 Mon 23 Sep 2019 11:28:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47479 Mon 23 Jan 2023 11:40:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:37007 ENO and symptoms (F_ENO group). Exacerbations were recorded prospectively. Height and weight were measured at baseline, and in late pregnancy. GWG was categorized according to Institute of Medicine guidelines. A validated parent-completed questionnaire assessed infant wheeze-related outcomes. Results: F_ENO-based management was associated with a significantly lower incidence rate ratio for maternal exacerbations in nonobese mothers (0.52, 95% confidence interval [CI], 0.31-0.88, P = .015, n = 129), and women with GWG within recommendations (0.35, 95% CI, 0.12-0.96, P = .042, n = 43), but not for obese mothers (0.59, 95% CI, 0.32-1.08, P = .089, n = 88), or women with excess GWG (0.58, 95% CI, 0.32-1.04, P = .07, n = 104). Recurrent bronchiolitis occurred in 5.3% (n = 1) of infants born to non-overweight mothers, 16.7% (n = 3) of infants of overweight mothers, and 21.7% (n = 5) of infants of obese mothers in the control group. In the F_ENO group, 2 infants of obese mothers had recurrent bronchiolitis (7.1%, P = .031). Conclusions: The benefits of F_ENO-based management are attenuated among obese mothers and those with excess GWG, indicating the importance of weight management in contributing to improved asthma management in pregnancy.]]> Mon 14 Nov 2022 20:28:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46232 Mon 14 Nov 2022 12:33:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55058 Mon 08 Apr 2024 09:43:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:40099 χ² tests and logistic regression models, adjusting for confounders, were utilized. Data were complete for 605 participants at T1 and 486 (80%) at T2. Of 605 participants: 89% initiated breastfeeding and 38% breastfed for more than 6 months. Breastfeeding for more than 6 months vs “never” was associated with a reduced adjusted relative risk of infant wheeze at T1 (0.54, 95% confidence interval, 0.30‐0.96). Bronchiolitis risk was reduced at T1 and T2 with more than 6 months of breastfeeding vs “never.” Breastfeeding duration of 1 to 3 months, 4 to 6 months, and more than 6 months were associated with a reduced risk of infant healthcare utilization (all P < .05, vs “never”), but not medication use (P > .05). Breastfeeding for more than 6 months was associated with a reduced risk of wheeze, bronchiolitis, and wheeze‐related healthcare utilization in infants at risk due to maternal asthma. Notably, breastfeeding for shorter durations was associated with a reduced risk of healthcare utilization compared with none. Larger cohorts are needed to further examine the impact of breastfeeding exposure on respiratory health in infants exposed to maternal asthma.]]> Mon 06 May 2024 11:07:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:23240 Fri 22 Apr 2022 10:21:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39682 Fri 17 Jun 2022 15:46:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46047 Fri 11 Nov 2022 14:11:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46080 Fri 11 Nov 2022 10:10:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55056 Fri 05 Apr 2024 14:28:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45534 Fri 04 Nov 2022 14:45:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45561 Fri 04 Nov 2022 14:44:44 AEDT ]]>